Evidence map›Paper›PMID 35697329›Full record

ArticleCancer letters2022

Versican secreted by the ovary links ovulation and migration in fallopian tube derived serous cancer.

Angela Russo, Zizhao Yang, Georgette Moyle Heyrman, Brian P Cain, Alfredo Lopez Carrero, Brett C Isenberg, Matthew J Dean, Jonathan Coppeta, Joanna E Burdette

Open access · greenAbstract read
In one paragraph

Article in Cancer letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Angela RussoDepartment of Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL, 60607, USA. Electronic address: russoa@uic.edu.
Zizhao YangDepartment of Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL, 60607, USA.
Georgette Moyle HeyrmanDepartment of Chemistry, University of Wisconsin, Green Bay, WI, 54311, USA.
Brian P CainCharles Stark Draper Laboratory, Cambridge, MA, 02139, USA.
Alfredo Lopez CarreroDepartment of Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL, 60607, USA.
Brett C IsenbergCharles Stark Draper Laboratory, Cambridge, MA, 02139, USA.
Matthew J DeanDepartment of Animal Sciences, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
Jonathan CoppetaCharles Stark Draper Laboratory, Cambridge, MA, 02139, USA.
Joanna E BurdetteDepartment of Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL, 60607, USA.
University of Illinois Chicago · USDraper Laboratory · USUniversity of Illinois Urbana-Champaign · USUniversity of Wisconsin–Green Bay · US

Funding

Microfluidic Models of Ovarian Cancer Preneoplastic LesionsR01CA240301 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Joanna E Burdette, Jonathan Coppeta · 2019 to 2026
$4.6M
Imaging mass spectrometry methodologies for studying the metabolites of cancer metastasisR01CA240423 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BURDETTE, JOANNA E, SANCHEZ, LAURA MARGARET · 2020 to 2024
$2.1M
UIC Portal to Biomedical Research Careers (UIC PBRC) PREPR25GM121212 · NIGMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALFONSO, AIXA, FEDERLE, MICHAEL J · 2018 to 2024
$1.8M
NCI NIH HHS R01 CA240301NCI NIH HHS R01 CA240423NIGMS NIH HHS R25 GM121212
6 · The paper itself

Abstract

High grade serous ovarian cancers (HGSOC) predominantly arise in the fallopian tube epithelium (FTE) and colonize the ovary first, before further metastasis to the peritoneum. Ovarian cancer risk is directly related to the number of ovulations, suggesting that the ovary may secrete specific factors that act as chemoattractants for fallopian tube derived tumor cells during ovulation. We found that 3D ovarian organ culture produced a secreted factor that enhanced the migration of FTE non-tumorigenic cells as well as cells harboring specific pathway modifications commonly found in high grade serous cancers. Through size fractionation and a small molecule inhibitors screen, the secreted protein was determined to be 50-100kDa in size and acted through the Epidermal Growth Factor Receptor (EGFR). To correlate the candidates with ovulation, the PREDICT organ-on-chip system was optimized to support ovulation in a perfused microfluidic platform. Versican was found in the correct molecular weight range, contained EGF-like domains, and correlated with ovulation in the PREDICT system. Exogenous versican increased migration, invasion, and enhanced adhesion of both murine and human FTE cells to the ovary in an EGFR-dependent manner. The identification of a protein secreted during ovulation that impacts the ability of FTE cells to colonize the ovary provides new insights into the development of strategies for limiting primary ovarian metastasis.

Indexed as

Cystadenocarcinoma, SerousFallopian Tube NeoplasmsOvarian NeoplasmsAnimalsErbB ReceptorsFallopian TubesFemaleHumansMiceOvulationVersicansErbB ReceptorsVersicansEGFRFallopian tubeMigrationOvulationVersican

Identifiers

PMID35697329
PMCPMC10134877
OpenAlexW4281884845

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.